Eleonora Calabretta

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Defibrotide for Protecting Against and Managing Endothelial Injury in Hematologic Malignancies and COVID-19.

Defibrotide for Protecting Against and Managing Endothelial Injury in Hematologic Malignancies and COVID-19.

Journal: Biomolecules

Published: May 02, 2025

Regulatory factor X 7 limits Myc activity during B cell activation and suppresses Myc-dependent lymphomagenesis.

Regulatory factor X 7 limits Myc activity during B cell activation and suppresses Myc-dependent lymphomagenesis.

Journal: Nature immunology

Published: March 07, 2025

The immune cell dynamics in the peripheral blood of cHL patients receiving anti-PD1 treatment.

The immune cell dynamics in the peripheral blood of cHL patients receiving anti-PD1 treatment.

Journal: Frontiers in oncology

Published: October 28, 2024

A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA.

A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA.

Journal: Blood

Published: October 23, 2024

DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma.

DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma.

Journal: Blood

Published: June 04, 2024

Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide.

Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide.

Journal: Blood reviews

Published: May 01, 2024

Use of defibrotide in COVID-19 pneumonia: comparison of a phase II study and a matched real-world cohort control.

Use of defibrotide in COVID-19 pneumonia: comparison of a phase II study and a matched real-world cohort control.

Journal: Haematologica

Published: February 27, 2024

Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma.

Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma.

Journal: Nature communications

Published: February 07, 2024

Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma.

Baseline circulating tumour DNA and interim PET predict response in relapsed/refractory classical Hodgkin lymphoma.

Journal: British journal of haematology

Published: August 13, 2023

Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics.

Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics.

Journal: British journal of haematology

Published: January 26, 2022

The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma.

The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma.

Journal: Blood

Published: November 02, 2021

Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes.

Defibrotide: potential for treating endothelial dysfunction related to viral and post-infectious syndromes.

Journal: Expert opinion on therapeutic targets

Published: June 25, 2021

Showing 1-12 of 15

Last Updated: 09/26/2026